ULTOMIRIS 1100 mg/11 ml CONCENTRADO PARA SOLUCION PARA PERFUSION

( ARTG ) Ultomiris is indicated:, for the treatment of patients with Paroxysmal Nocturnal Haemoglobinuria (PNH), for the treatment of patients with Atypical Haemolytic Uraemic Syndrome (aHUS), as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive., for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive.,Ultomiris is not intended for the acute treatment of a NMOSD relapse.